Latest News for: nsclc

Edit

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

PR Newswire 11 Feb 2026
EGFR-NSCLC Market Summary The market size for EGFR-NSCLC was found to be USD 6 billion in the leading markets in 2024 ... The total number of incident cases of EGFR-NSCLC in the leading market was nearly 117,000 in 2024 ... What is EGFR-NSCLC?.
Edit

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC (Form 6-K) (Immutep Ltd)

Public Technologies 10 Feb 2026
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC • ... Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).
Edit

NSCLC Clinical Trial Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight

GetNews 10 Feb 2026
DelveInsight’s "NSCLC Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape ... NSCLC Overview ... NSCLC Emerging Drugs Profile V940 ... NSCLC Companies.
Edit

EGFR + NSCLC Clinical Trial Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics ...

GetNews 09 Feb 2026
It covers the EGFR + NSCLC pipeline drug profiles, including clinical and nonclinical stage products ... Explore our latest breakthroughs in EGFR + NSCLC research ... Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments.
Edit

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Nasdaq Globe Newswire 06 Feb 2026
... and chemotherapy as first line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC).
Edit

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC (Immutep Ltd)

Public Technologies 06 Feb 2026
) Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC ... Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).
Edit

Opdivo® (nivolumab) with chemotherapy before surgery then alone after surgery recommended for use on the NHS when treating adult patients with resectable NSCLC

Pharmiweb 21 Jan 2026
... Health and Care Excellence (NICE) to treat adult patients with resectable non-small cell lung cancer (NSCLC).1 ... It is estimated that approximately 85% of people with lung cancer have a form of NSCLC.2.
Edit

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

Pharmiweb 20 Jan 2026
The IMMUNOLIFE trial is evaluating MaaT033 in combination with CB vs BIC in 162 patients with advanced NSCLC who are refractory to immune checkpoint inhibitors (ICIs) and have received antibiotics.
Edit

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC (Summit Therapeutics Inc)

Public Technologies 12 Jan 2026
FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC ... locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Edit

Immunotherapy Plus Surgery Benefits Lung Cancer Patients

Mega Doctor News 12 Jan 2026
Results from the exploratory analysis of the CheckMate 77T trial, published today in Nature Cancer, found that clinical outcomes were similar in patients with and without N2 NSCLC ... What does this mean for patients with operable stage III N2 NSCLC?.
Edit

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Pharmiweb 07 Jan 2026
... advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) ... “While outcomes for patients with NSCLC have significantly improved over the last decade, we know there is more work to do.
Edit

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

PR Newswire 05 Jan 2026
OptiTROP-Lung05 is the first Phase III study of an immunotherapy and ADC combination to meet its primary endpoint in the first-line treatment of NSCLC.
Edit

Cofactor Genomics Advances Predictive Cancer Diagnostics With Landmark OncoPrism-NSCLC Study

Business Wire 18 Dec 2025
... the PREDAPT non-small cell lung cancer (NSCLC) trial validating the company’s OncoPrism-NSCLC test.
Edit

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC (Nuvectis Pharma Inc)

Public Technologies 17 Dec 2025
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC ... Phase 1b of NXP900 in Combination with Osimertinib in Patients with EGFRmut+ NSCLC.
Edit

ESMO ASIA | HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 11 Dec 2025
HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC ... (NSCLC). About NSCLC.

Article Search

tools
×
×
×
×